Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
ViewAttendees 6

Session: HIV Clinical State of the Art: At the Cutting Edge

In the Pipeline: New Drugs for HIV Treatment

Thursday, September 30, 2021
11:00 AM - 12:15 PM EDT
Participants should be aware of the following financial/non-financial relationships:
Melanie A. Thompson, MD: Cepheid, Inc (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support; Cytodyn, Inc (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support; Frontier Biotechnologies (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support; Gilead Sciences (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support; Merck Sharp Dohme (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support; ViiV Healthcare (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support

    Speaker(s)

  • Melanie A. Thompson, MD

    Principal Investigator
    AIDS Research Consortium of Atlanta
    Atlanta, GA, United States

    Cepheid, Inc (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support; Cytodyn, Inc (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support; Frontier Biotechnologies (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support; Gilead Sciences (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support; Merck Sharp Dohme (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support; ViiV Healthcare (Individual(s) Involved: Self): Fees for conduct of clinical trials paid to AIDS Research Consortium of Atlanta, Research Grant or Support